tirzepatide clinical trials near me New trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Tirzepatide trial shows additional 21.1%

"The criteria for treatment of obesity with telehealth is exactly the same for treatment in a doctor's office," Aronne said

J., Kim, A., Miller, K

That's why we've created a program that combines medication with personalized support and guidance

Metformin has decades of data on modest weight neutrality and possible cardiovascular protection

For all experimental groups, treatments were administered in a counter-balanced, within-subject design and injection days were separated by 72 hours

Managing side effects during dose escalation Side effects are part of the tirzepatide experience for most users, particularly during dose escalation